US accelerates psychedelic research amid colonial legacies and profit-driven biomedical extraction: systemic risks of ibogaine and beyond

health Nature 21 Apr 2026 CMR 4/7 via mistral

Mainstream coverage frames psychedelic research as a biomedical breakthrough, obscuring its entanglement with historical colonial extraction of psychoactive plants and the neoliberal commodification of consciousness. The focus on ibogaine—a compound derived from the African iboga shrub—ignores how Western science often sidelines indigenous knowledge systems while repurposing sacred plants for pharmaceutical profit. Structural inequities in research funding and ethical oversight risk repeating patterns seen in Big Pharma’s exploitation of traditional medicine, particularly in Global South contexts where these substances originate.

⚡ Power-Knowledge Audit

The narrative is produced by Western scientific institutions (e.g., Nature, NIH) and pharmaceutical interests, serving a biomedical-industrial complex that prioritizes patentable treatments over holistic or indigenous frameworks. Framing psychedelics as 'mind-altering drugs' reinforces stigma while positioning the US as a leader in their 'safe' commercialization. This obscures the role of colonial histories in the appropriation of psychoactive plants and the power imbalances in global knowledge production, where Global South communities bear the ecological and cultural costs of extraction.

📐 Analysis Dimensions

Eight knowledge lenses applied to this story by the Cogniosynthetic Corrective Engine.

Indigenous Knowledge

90%

Iboga’s cultural and spiritual significance in Bwiti traditions of Gabon and Cameroon is reduced to a 'mysterious compound' in Western discourse, erasing centuries of indigenous pharmacopeia and ethical frameworks. The iboga shrub’s overharvesting for pharmaceutical research mirrors colonial extraction of quinine and rubber, where Global South ecosystems and knowledge systems were treated as infinite resources. Indigenous healers warn that ibogaine’s clinical isolation strips the plant of its holistic healing properties, which require ritual context and community support to mitigate risks like cardiac toxicity.

Historical Parallels

80%

The US’s renewed interest in psychedelics echoes Cold War-era programs like MK-Ultra, where mind-altering substances were weaponized for psychological control, revealing a pattern of state-sponsored experimentation on marginalized groups. The 1960s criminalization of psychedelics under Nixon’s War on Drugs was not a public health measure but a tool to suppress countercultural movements, particularly Black and Indigenous activists. Colonial histories of plant extraction—from coca to opium—show how Western biomedicine has repeatedly co-opted traditional remedies while criminalizing their cultural use.

Cross-Cultural Wisdom

70%

In West Africa, iboga is revered as a bridge to the spirit world, with ceremonies lasting days and involving communal participation, contrasting sharply with the clinical, time-limited trials in the US. Amazonian ayahuasca traditions, though increasingly commodified, maintain reciprocal relationships with the vine and chacruna plant, emphasizing ecological stewardship—a concept absent in Western bioprospecting. In India, traditional Ayurvedic use of psychedelic plants like *Soma* or *Datura* is framed within spiritual and medicinal cosmologies, whereas Western research often divorces these substances from their cultural contexts.

Scientific Evidence

60%

Psychedelics like psilocybin and MDMA show promise for treating PTSD and depression, but ibogaine’s cardiac risks—including QT prolongation and fatal arrhythmias—are understudied in clinical settings. The US’s push for 'streamlined' research risks bypassing rigorous Phase I trials, repeating errors seen in early MDMA trials where safety protocols were inadequate. Western scientific paradigms often prioritize isolated compounds over whole-plant medicines, despite evidence that entourage effects (e.g., in ayahuasca) enhance therapeutic outcomes.

Artistic & Spiritual

50%

Psychedelics have long inspired artistic movements, from the surrealist experiments of Antonin Artaud to the visionary art of Alex Grey, but Western commercialization risks reducing these experiences to 'trip reports' or 'microdosing trends.' Indigenous traditions view psychedelics as sacred teachers, not tools for productivity, as seen in the Shipibo-Conibo people’s geometric art inspired by ayahuasca visions. The spiritual dimensions of these substances—such as ego dissolution or communion with ancestors—are often pathologized in biomedical frameworks, flattening their transformative potential.

Future Modelling

80%

If unchecked, the psychedelic industry could replicate Big Pharma’s monopolistic practices, pricing out Global South communities from access to their own traditional medicines while profiting from their appropriation. Scenario modeling suggests that ibogaine’s commercialization could lead to monoculture cultivation, displacing local farmers and biodiversity, similar to the quinoa or avocado booms. Conversely, a decolonial approach—prioritizing indigenous-led research and equitable benefit-sharing—could redefine mental health care, integrating ancestral knowledge with modern science.

Marginalised Voices

90%

Black and Indigenous communities, historically targeted by drug policies, are now being courted as 'trial participants' in psychedelic research without adequate safeguards or reparative justice. African and Amazonian healers are rarely credited as co-authors in Western studies, despite their centuries of expertise in safe administration. The criminalization of psychedelics has disproportionately harmed marginalized groups, yet their voices are excluded from policy discussions on decriminalization or therapeutic access.

🔍 What's Missing

The original framing omits the colonial extraction of iboga from Gabon and Cameroon, the erasure of Bwiti spiritual practices in Central Africa, and the lack of Free, Prior, and Informed Consent (FPIC) in research. It also ignores historical parallels like the 1950s-60s CIA’s MK-Ultra program using psychedelics for psychological warfare, or the 19th-century opium trade’s exploitation of Asian medicinal traditions. Marginalized voices—such as African healers, Amazonian ayahuasca practitioners, or Black and Indigenous communities disproportionately targeted by drug policies—are absent. The systemic risks of pharmaceutical monopolization and the environmental impact of iboga cultivation are also overlooked.

An ACST audit of what the original framing omits. Eligible for cross-reference under the ACST vocabulary.

🛠️ Solution Pathways

01
Decolonizing Psychedelic Research: Indigenous-Led Governance
Establish international ethical frameworks requiring Free, Prior, and Informed Consent (FPIC) for all research involving traditional psychoactive plants, with indigenous communities co-leading study design and benefit-sharing agreements. Fund indigenous-led clinics and training programs to ensure culturally competent care, modeled after successful programs like the Amazon’s Takiwasi Center. Mandate that 20% of research funding be allocated to indigenous knowledge holders and their institutions.
02
Equitable Benefit-Sharing and Anti-Exploitation Policies
Enforce strict regulations against biopiracy, requiring pharmaceutical companies to share profits with source communities (e.g., Gabon’s iboga harvesters) and reinvest in local conservation. Create a global registry of traditional uses of psychedelic plants to prevent patenting of indigenous knowledge, similar to the Nagoya Protocol’s access and benefit-sharing mechanisms. Support agroecological farming of iboga and ayahuasca to prevent monoculture and ensure sustainable supply chains.
03
Integrating Holistic and Biomedical Frameworks
Develop hybrid treatment models that combine clinical psychedelic therapy with indigenous healing practices, such as Bwiti ceremonies or Amazonian dieta protocols, under strict safety monitoring. Train therapists in cultural humility and trauma-informed care to address the historical harms of psychedelic criminalization on marginalized groups. Prioritize research on whole-plant medicines (e.g., ayahuasca) over isolated compounds to preserve entourage effects and reduce side effects.
04
Policy Reform: Decriminalization with Community Control
Advocate for state-level decriminalization of psychedelics (e.g., Oregon’s psilocybin model) with community advisory boards to prevent corporate capture and ensure equitable access. Redirect drug war funding to harm reduction programs and indigenous healing centers. Implement restorative justice measures for those harmed by psychedelic prohibition, including expungement of past convictions and reparations for affected communities.

🧬 Integrated Synthesis

The US’s acceleration of psychedelic research is not merely a biomedical breakthrough but a reenactment of colonial extraction and neoliberal commodification, where ibogaine’s 'mysterious' allure obscures its roots in Gabon’s Bwiti traditions and the ecological violence of overharvesting. This narrative serves pharmaceutical interests and state power structures that have historically weaponized mind-altering substances—from MK-Ultra to the War on Drugs—while sidelining the very communities that safeguarded these plants for centuries. A systemic solution requires dismantling the biomedical-industrial complex’s dominance, replacing it with indigenous-led governance, equitable benefit-sharing, and hybrid healing models that honor both scientific rigor and ancestral wisdom. Without this, the psychedelic renaissance risks becoming another chapter in the exploitation of Global South resources and knowledge, perpetuating cycles of harm under the guise of progress. The path forward demands reparative justice, not just clinical trials—centering the voices of those who have stewarded these medicines long before Western science took notice.

🔗

Read the original story at Nature

https://www.nature.com/articles/d41586-026-01286-1

⚡ Power-Knowledge Audit

📐 Analysis Dimensions

🔍 What's Missing

🛠️ Solution Pathways

Decolonizing Psychedelic Research: Indigenous-Led Governance

Equitable Benefit-Sharing and Anti-Exploitation Policies

Integrating Holistic and Biomedical Frameworks

Policy Reform: Decriminalization with Community Control

🧬 Integrated Synthesis